Release – Comtech Telecommunications Corp. Declares $0.10 Per Common Share Quarterly Cash Dividend



Comtech Telecommunications Corp. Declares $0.10 Per Common Share Quarterly Cash Dividend

Research, News, and Market Data on Comtech Telecommunications

MELVILLE, N.Y.–(BUSINESS WIRE)–Jun. 9, 2022– 
June 9, 2022
— 
Comtech Telecommunications Corp. (NASDAQ: CMTL) announced today that its Board of Directors declared a quarterly cash dividend of 
$0.10 per common share, payable on 
August 19, 2022
, to shareholders of record at the close of business on 
July 20, 2022. The dividend is the Company’s forty-eighth consecutive quarterly dividend. Future common stock dividends remain subject to compliance with financial covenants under the Company’s secured credit facility, as well as Board approval and certain voting rights of holders of our Series A Convertible Preferred Stock.

Comtech Telecommunications Corp. is a leading global provider of next-generation 911 emergency systems and secure wireless communications technologies to commercial and government customers around the world. Headquartered in 
Melville, New York and with a passion for customer success, 
Comtech designs, produces and markets advanced and secure wireless solutions. For more information, please visit www.comtech.com.

Certain information in this press release contains statements that are forward-looking in nature and involve certain significant risks and uncertainties. Actual results could differ materially from such forward-looking information. The Company’s 
Securities and Exchange Commission filings identify many such risks and uncertainties. Any forward-looking information in this press release is qualified in its entirety by the risks and uncertainties described in such 
Securities and Exchange Commission filings.

PCMTL

Investor Contact Robert Samuels robert.samuels@comtech.com
(631) 962-7102

Source: 
Comtech Telecommunications Corp.


Release – Avivagen Announces Successful Completion of Formal Safety and Toxicology Evaluation of Fully Oxidized Beta-Carotene (OxBC)



Avivagen Announces Successful Completion of Formal Safety and Toxicology Evaluation of Fully Oxidized Beta-Carotene (OxBC)

Research, News, and Market Data on Avivagen

Ottawa, ON /Business Wire/ June 9, 2022 /- Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that it has completed a series of important safety evaluations of fully oxidized beta-carotene (OxBC), the proprietary and critical active ingredient in the company’s highly-regarded OxC-betaTM product line. Results of the Avivagen-initiated toxicology study, conducted following standardized and internationally recognized protocols, provided further evidence of the safety and effectiveness of OxBC and the OxC-betaTM product line for use in human and animal applications.

Based on previously conducted scientific testing, OxBC and Avivagen’s OxC-betaTM product line have achieved self-affirmed GRAS status in the United States and have already secured regulatory approval in a number of other important food and feed markets, including China, Brazil, Philippines, Mexico, Taiwan, New Zealand, Thailand, Vietnam, Australia, and Malaysia.

“Through extensive internal and third-party testing, and both regulatory evaluation and customer trial and adoption of our OxC-beta line around the globe, the safety of OxBC as an active ingredient supporting a wide range of beneficial uses for humans and animals has been shown again and again,” says Kym Anthony, Chief Executive Officer, Avivagen. “Already more than than 35 million livestock animals have seen enhanced health and productivity thanks to the OxBC ingredient, and over 82,000 dogs and 3,300 humans have enjoyed the benefits of OxBC products. As expected, proactively participating in this toxicology assessment has provided further evidence of the safety and effectiveness of our OxC-betaTM line and presents a valuable indicator of the significant commercialization opportunities for our technology as we continue to expand approvals and adoptions in new markets worldwide.”

While there have been zero reports of product-related adverse events from OxBC or OxC-betaTM to date, the present toxicology tests were initiated by Avivagen to further reinforce OxBC’s applicability as a very safe ingredient in a wide range of products and provide further formal evidence to support continued regulatory approval and adoption in both new jurisdictions and product applications. Toxicology testing consisted of three separate studies, all of which are conducted in animals, typically rats. The first test demonstrated that in rats the maximum tolerated single oral dose of OxBC and the LD50 were 5,000 and 30,079 mg/kg body weight, respectively. The second test, a 14-day, repeat-dose acute oral toxicity test demonstrated an initial No Observable Adverse Effect Level (NOAEL) of OxBC of 1,250 mg/kg body weight. In the third and final test, no mortality or morbidity was observed for administration by oral gavage of OxBC up to 1875 mg/kg body weight once daily in male and female Sprague Dawley rats for 90 consecutive days followed by a 28-day recovery period. There were no treatment-related adverse effects on body weight, feed consumption, hematology, coagulation, hormonal, and clinical chemistry parameters and organ weights. No gross pathological abnormalities nor adverse histopathological findings were observed. The NOAEL was determined to be 1875 mg/kg body weight. These findings strongly support the safety of OxBC, especially considering the NOAEL value exceeds by several thousand times the daily level of approximately 0.5 mg/kg body weight of OxBC used in supplementing livestock, canines, felines and humans.

About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about ?-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements
This news release includes
certain forward-looking statements that are based upon the current expectations
of management. Forward-looking statements involve risks and uncertainties
associated with the business of Avivagen Inc. and the environment in which the
business operates. Any statements contained herein that are not statements of
historical facts may be deemed to be forward-looking, including those
identified by the expressions “aim”, “anticipate”, “appear”, “believe”,
“consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”,
“likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”,
“whether”, “will”, “would” and similar expressions.

Statements set out in this news release relating to the future
growth and prospects for Avivagen and the possibility for OxC-beta™ Livestock
to replace antibiotics in livestock feeds as growth promoters are
forward-looking statements. These forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results or events to
differ materially from current expectations. For instance, Avivagen’s products
may not gain market acceptance or regulatory approval in new jurisdictions or
for new applications and may not be widely accepted as a replacement for
antibiotics as growth promoters in livestock feeds due to many factors, many of
which are outside of Avivagen’s control. Readers are referred to the risk
factors associated with the business of Avivagen set out in Avivagen’s most
recent management’s discussion and analysis of financial condition available at
www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to
update the forward-looking statements, or to update the reasons why actual
results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.
Drew Basek
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com

Kym Anthony

Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164

Website: www.avivagen.com
Copyright © 2022 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.


Release – TAAL to Webcast Live at the OTCQX Best 50 Virtual Investors Conference June 16



TAAL to Webcast Live at the OTCQX Best 50 Virtual Investors Conference June 16

Research, News, and Market Data on TAAL

TAAL invites individual and institutional
investor as well as advisors and analysts to attend the interactive
presentation at VirtualInvestorConferences.com

TORONTO, June 9, 2022 /CNW/ – TAAL Distributed Information Technologies Inc. (CSE:TAAL) (FWB:9SQ1) (OTC:TAALF) (“TAAL” or the “Company”), a vertically integrated blockchain infrastructure and service provider for enterprise, announces that CEO Richard Baker will present live at the OTCQX Best 50 Virtual Investors Conference on June 16, 2022 at 11am Eastern Time (details below).  Mr. Baker will also host 1×1 investor meetings through the event.

“TAAL is building the infrastructure needed to power the next generation of the internet,” said CEO, Richard Baker. “We believe in a future beyond block subsidy rewards where revenues are driven by transaction processing and we are on a path to become a major network provider for Web 3.0 and the digital economy; I look forward to sharing this and more with investors at the OTCQX Best 50 conference.”   

Recent Company Highlights

  • Gross revenue from hashing operations was $8.7 million, a $7.8 million increase from $0.9 million compared to the first quarter of the prior year (“Q1 2021”). 
  • Adjusted EBITDA loss of $0.9 million versus a $3.5 million loss in Q1 2021.
  • TAAL processed over 232 million transactions within 9,595 blocks on the BSV network for the quarter, earning almost $0.3 million in additional rewards from transaction processing, representing 3% of total revenue.
  • Future growth secured with deposits for plant and equipment of $34.7 million to expand hashing fleet and a clean energy data center in New Brunswick, Canada.
  • As of March 31, 2022, TAAL had about 23,000 BSV, 600 BCH and 0.5 BTC in coin treasury.

TAAL Investor
Presentation Webcast

DATE: Thursday June 16, 2022

TIME: 11:00am EST
LINK: https://bit.ly/3MB962u

Available for 1×1 meetings: Friday June 17, 2022.

This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

About TAAL Distributed
Information Technologies Inc.

TAAL Distributed Information Technologies Inc. delivers value-added blockchain services, providing professional-grade, highly scalable blockchain infrastructure and transactional platforms to support businesses building solutions and applications upon the BitcoinSV platform, and developing, operating, and managing distributed computing systems for enterprise users.

Visit TAAL online at www.taal.com/investors 

About Virtual Investor
Conferences
®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access.  Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

SOURCE Taal Distributed Information Technologies Inc.

For further information: Media and Investor Contact: TAAL, Richard Baker, Chief Executive Officer, Office: (437) 826-8889, Richard.Baker@taal.com; Sophic Capital, Sean Peasgood, President & Chief Executive Officer, Office: (437) 826-8889, Sean@SophicCapital.com


Release – Shareholders Approve All Resolutions at Aurania’s Annual and Special Meeting



Shareholders Approve All Resolutions at Aurania’s Annual and Special Meeting

Research, News, and Market Data on Aurania Resources

Toronto, Ontario, June 9, 2022 – Aurania Resources Ltd. (TSXV:
ARU) (OTCQB: AUIAF) (Frankfurt: 20Q) (“Aurania” or the “Company”)
 is pleased to announce that its shareholders have approved all resolutions at the Company’s Annual and Special Meeting (the “Meeting”) which was held on June 8, 2022.

At the Meeting, shareholders approved the financial statements for the year-ended December 31, 2021, and the report of the auditors thereon, the appointment of auditors, election of directors and the Company’s incentive stock option plan for the upcoming year.  Details of these matters are disclosed in the Management Information Circular for the Meeting dated April 28, 2022, and posted under the Company’s profile on www.sedar.com and on the Company’s corporate website 
http://www.aurania.com/investors/annual-general-meeting/.

The formal part of the Meeting was followed by a presentation and a brief question-and-answer period.  The webcast replay is available now and can be accessed until September 8, 2022, via the original webcast link. The audio-only replay will be available in the coming days and will be posted on Aurania’s website.  Forward-looking statements were made during the activities update and question-and-answer period.

About Aurania

Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition and exploration of mineral property interests, with a focus on precious metals and copper in South America.  Its flagship asset, The Lost Cities – Cutucu Project, is located in the Jurassic Metallogenic Belt in the eastern foothills of the Andes mountain range of southeastern Ecuador.

Information on Aurania and technical reports are available at www.aurania.com and www.sedar.com, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at  
https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir

VP Investor Relations

Aurania Resources Ltd.

(416) 367-3200

carolyn.muir@aurania.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Forward-Looking Statements

This news release may contain forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurania. Forward-looking statements include estimates and statements that describe Aurania’s future plans, objectives or goals, including words to the effect that Aurania or its management expects a stated condition or result to occur. Forward-looking statements may be identified by such terms as “believes”, “anticipates”, “expects”, “estimates”, “may”, “could”, “would”, “will”, or “plan”. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although these statements are based on information currently available to Aurania, Aurania provides no assurance that actual results will meet management’s expectations. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to Aurania’s objectives, goals or future plans, statements, exploration results, potential mineralization, the corporation’s portfolio, treasury, management team and enhanced capital markets profile, the estimation of mineral resources, exploration, timing of the commencement of operations and estimates of market conditions. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, failure to identify mineral resources, failure to convert estimated mineral resources to reserves, the inability to complete a feasibility study which recommends a production decision, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, regulatory, environmental or other project approvals, political risks, inability to fulfill the duty to accommodate indigenous peoples, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, changes in exchange rates, fluctuations in commodity prices, delays in the development of projects, capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry, the effects of COVID-19 on the business of the Company including but not limited to the effects of COVID-19 on the price of commodities, capital market conditions, restrictions on labour and international travel and supply chains, and those risks set out in Aurania’s public documents filed on SEDAR. Although Aurania believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Aurania disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.


Aurania Resources (AUIAF) – Highlights from the Annual Shareholder Meeting

Thursday, June 09, 2022

Aurania Resources (AUIAF)
Highlights from the Annual Shareholder Meeting

Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Annual General Meeting. Aurania hosted the annual meeting of shareholders on June 8 which was accessible via conference call and webcast. Management summarized its immediate exploration strategy, including further prospecting at epithermal gold targets and refining porphyry copper targets in preparation for drilling. Following completion of an environmental impact statement, drilling could commence at copper targets Awacha and Tatasham in the fourth quarter of 2022. While the Kuri Yawi and Kuripan remain high priority gold targets, the discovery of alluvial gold near the location of a historic gold mining center puts attention on other upstream gold targets within Aurania’s concession block. 

Working back to the source. Based on collaborative work with Metron Incorporated, the inferred location of historic gold mining center Logrono de los Caballeros, has been identified. Logrono is one of two, the other being Sevilla de Oro, historic gold mining centers that were thought to be within Aurania’s concession block in Ecuador. While the site is not on Aurania’s concession block, it is downstream and Aurania intends to locate Logrono’s source of alluvial gold….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

New EV Charging Station Proposal by White House


Image Credit: RoK (Flickr)


White House Plans to Make EV Ownership Easier is of Interest to Investors

The dream of care-free travel, at low cost and low environmental impact, in an electric vehicle (EV) just got a little closer to reality. The White House has announced (June 6) guidelines intended to standardize charging stations while using tax dollars to make these stations more available and reliable. The proposal outlines what new charging stations need to have to qualify for access to the billions being spent on infrastructure. The initial intent is to help create 500,000 charging stations along major arteries in 5 years at the cost of $5 billion. The standards do not match the current largest charging network and standards produced by Tesla, Inc. (TSLA).

About Biden’s Proposal

The White House aims to standardize the chargers by making sure that federally subsidized outlets all offer similar payment systems, charging speeds, pricing information, and functionality. The idea, according to the Department of Transportation (DOT), is to ensure ease of charging regardless of the brand of car, state, or roadway.

Under the rules, charging stations will not be allowed to require membership for use. The White House also laid out standards for how charging stations should be maintained over time; the intent is to reduce the persistent problem of broken chargers.

One of the biggest charging providers currently in the US does match the criteria under the new standards. Tesla Motors chargers with proprietary connections do not qualify, it isn’t clear if the company will succumb to the Washington standard or continue with its proprietary outlets.

The push forward of this plan for 500,000 charging stations is worth the attention of investors in both materials and car manufacturers. The increasing adoption of electric infrastructure and batteries could provide significant growth opportunity for investors in EVs, and producers of copper, stainless steel, aluminum, nickel, chrome, cobalt, and lithium, as well as manufacturers of polycarbonates, elastomers, and thermoplastics polyurethanes used for critical manufacturing components of EV charging stations, such as enclosures, cables, connectors, cable insulation and jacketing, and flexible conduits.

Take Away

Federal subsidies were announced that would be made available to build out the EV charging station network to provide a more attractive and cost-effective experience to help induce more purchases of electric vehicles.

The $5 billion being made available requires uniformity to ensure a similar experience and not provide a preference to one manufacturer over another.

The enormous amounts being spent by governmental agencies for this project should regain the attention of investors in metals and miners. Providers of other materials used in the construction of charging stations that could likely win a government contract are also worth analyzing.

Paul Hoffman

Managing Editor, Channelchek


Suggested Reading



Lithium Inflation and Availability Concerns Elon Musk



Enough US Produced Lithium to Exceed Today’s Demand





The Appeal of EVs with Bidirectional Charging



Copper Facing an Onslaught of Demand

Source

https://www.whitehouse.gov/briefing-room/statements-releases/2022/06/09/fact-sheet-biden-harris-administration-proposes-new-standards-for-national-electric-vehicle-charging-network/

https://driveelectric.gov/resources/

https://www.meticulousresearch.com/product/ev-charging-station-raw-materials-market-5200

https://www.fhwa.dot.gov/environment/alternative_fuel_corridors/resources/nprm_evcharging_unofficial.pdf

Stay up to date. Follow us:

 

Defense Metals Corp. (DFMTF) – 2022 Diamond Drilling Program in Full Swing

Wednesday, June 08, 2022

Defense Metals Corp. (DFMTF)
2022 Diamond Drilling Program in Full Swing

Defense Metals Corp. is a mineral exploration and development company focused on the acquisition, exploration and development of mineral deposits containing metals and elements commonly used in the electric power market, defense industry, national security sector and in the production of green energy technologies, such as, rare earths magnets used in wind turbines and in permanent magnet motors for electric vehicles. Defense Metals owns 100% of the Wicheeda Rare Earth Element Property located near Prince George, British Columbia, Canada. Defense Metals Corp. trades in Canada under the symbol “DEFN” on the TSX Venture Exchange, in the United States, under “DFMTF” on the OTCQB and in Germany on the Frankfurt Exchange under “35D”.

Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Drills are turning. Defense Metals has commenced diamond drilling at its Wicheeda Rare Earth Element (REE) deposit and expects to complete up to 5,000 meters of drilling to delineate existing resources and test near deposit exploration targets. Geotechnical and hydrogeological drilling will help optimize the open pit design and collect additional material for metallurgical test work. The 2022 drilling may include up to 1,500 meters of pit geotechnical and hydrogeological drilling, 1,500 meters of resource delineation and near resource exploration drilling, and up to 2,000 meters of PQ core for metallurgical testing. Results will be incorporated, along with results from the 2021 drill program, into a preliminary feasibility study (PFS) to be released during the first half of 2023.

Expanding and upgrading resources. The current NI 43-101 Preliminary Economic Assessment highlights 5.0 million tonnes of indicated resources averaging 2.95% total rare earth oxides (TREO) and 29.5 million tonnes of inferred resources averaging 1.83% TREO within a conceptual pit shell. The 2022 drill program has started from existing drill pads prepared during 2021 in the northern area of the Wicheeda REE deposit that returned some of the highest grade and width intercepts of the 2021 drilling program….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Tonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4th Symposium of the Canadian Society for Virology



Tonix Pharmaceuticals Announces Presentation on TNX-801 Vaccine Protection Against Monkeypox at the 4th Symposium of the Canadian Society for Virology

Research, News, and Market Data on Tonix Pharmaceuticals


Poster Presentation Includes Preclinical Data from Tonix’s Program to Develop a Vaccine for Monkeypox and Smallpox

CHATHAM, N.J., June 08, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Ryan Noyce, Ph.D., and David Evans, Professor, Department of Cell Biology, University of Alberta, together with scientists from Tonix presented data from a research collaboration between Tonix Pharmaceuticals and The University of Alberta in a poster presentation at the 4th Symposium of the Canadian Society for Virology held in Edmonton, Alberta, Canada on June 5, 2022. Copies of the poster are available on the Tonix Pharmaceuticals corporate website at www.tonixpharma.com.

The poster titled, “Synthetic
Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox,
” describes data from animals vaccinated with TNX-8011 to protect against monkeypox. The poster presentation reports that all animals (eight of eight) vaccinated with TNX-801 were fully protected with sterilizing immunity from a challenge with intra-tracheal monkeypox. The vaccinations with TNX-801 were well tolerated. Synthetic horsepox virus is the basis for the Company’s TNX-801 vaccine in development to protect against monkeypox and smallpox and for the Company’s Recombinant Pox Virus (RPV) platform to protect against other pathogens, including SARS-CoV-2.

“Our research work, in collaboration with Dr. Noyce and Professor Evans at The University of Alberta, shows that vaccination with TNX-801 has the ability to protect against monkeypox infection,” said Seth Lederman, M.D., President and Chief Executive Officer. “Monkeypox infection of humans was rare during the time people were vaccinated to protect against smallpox. After the eradication of smallpox, vaccination with live-virus vaccinia was stopped in most of the world. Monkeypox cases have been rising in Africa for several years. Very recently a strain of monkeypox from West Africa has caused clusters of monkeypox cases in many countries outside of Africa. We believe that vaccination with live-virus vaccines like TNX-801 has the potential to control monkeypox again.”

About TNX-801,
TNX-1840 and TNX-1850

TNX-801 is a live virus vaccine based on synthesized horsepox2,3. Tonix is developing TNX-801 for percutaneous administration as a vaccine to protect against monkeypox and smallpox. Tonix has previously reported positive data from a monkeypox challenge study in non-human primates4. Tonix is also developing TNX-1840 and TNX-1850 (horsepox-based live virus vaccines) for the prevention of COVID-19. TNX-1840 and TNX-1850 are designed to express the spike protein from the omicron and BA.2 variants of SARS-CoV-2, respectively. Tonix has previously reported positive data from a SARS-CoV-2 challenge study in non-human primates in which animals were vaccinated with TNX-1800, a horsepox-based vaccine expressing spike protein from the Wuhan strain5. Tonix’s TNX-801 was synthesized2 based on the sequence of the 1976 natural isolate Mongolian horsepox clone MNR-763. Molecular analysis of DNA sequences suggests that TNX-801 is closer than modern smallpox vaccines to the vaccine discovered and disseminated by Dr. Edward Jenner in 17986-8. For example, recent studies9,10 have shown approximately 99.7% colinear identity between TNX-801 and the circa 1860 U.S. smallpox vaccine VK05.11 The small plaque size in culture of TNX-801 appears identical to the U.S. Centers for Disease Control publication of the natural isolate12. Relative to vaccinia, horsepox has substantially decreased virulence in mice2. Dr. Edward Jenner invented vaccination in 1798 and the procedure was called “vaccination” because ‘cow’ is ‘vacca’ in Latin and the inoculum material was initially obtained from lesions on the udders of cows affected by a mild disease known as cowpox. However, Dr. Jenner suspected that cowpox originated from horses8. Subsequently, Dr. Jenner and others immunized against smallpox using material directly obtained from horses. The use of vaccines from horses was sometimes called ‘equination’ from the Latin ‘equus’ which means ‘horse’13. Equination and vaccination were practiced side-by-side in Europe
13,14.

About the
Recombinant Pox Virus (RPV) Platform

Horsepox virus and vaccines based on its use as a vector are live replicating viruses that elicit strong immune responses. Live replicating orthopoxviruses, like vaccinia or horsepox, can be engineered to express foreign genes and have been exploited as platforms for vaccine development because they possess; (1) large packaging capacity for exogenous DNA inserts, (2) precise virus-specific control of exogenous gene insert expression, (3) lack of persistence or genomic integration in the host, (4) strong immunogenicity as a vaccine, (5) ability to rapidly generate vector/insert constructs, (6) manufacturable at scale, and (7) ability to provide direct antigen presentation. Relative to vaccinia, horsepox has substantially decreased virulence in mice2. Horsepox-based vaccines are designed to be single dose, vial-sparing vaccines, that can be manufactured using conventional cell culture systems, with the potential for mass scale production and packaging in multi-dose vials. Tonix’s TNX-801 and RPV vaccine candidates are administered percutaneously using a two-pronged, or “bifurcated” needle. The major cutaneous reaction or “take” to vaccinia vaccine was described by Dr. Edward Jenner in 1796 and has been used since then as a biomarker for protective immunity to smallpox, including in the World Health Organization’s (WHO) accelerated smallpox eradication program that successfully eradicated smallpox in the 1960’s. The “take” is a measure of functional T cell immunity validated by the eradication of smallpox, a respiratory-transmitted disease caused by variola.

About
Monkeypox and Smallpox

Monkeypox15 and smallpox
16 are diseases in humans called by the monkeypox and smallpox (or variola) viruses, respectively. Monkeypox and variola are closely related orthopox viruses. Vaccination against smallpox with live virus vaccines based on horsepox or vaccinia protects against monkeypox. After routine smallpox vaccination was stopped in about 1970, monkeypox has become a growing problem in Africa. Recently approximately 300 cases have been identified outside of Africa.17 Smallpox is considered eradicated, but there are concerns about malicious reintroduction.

About Tonix
Pharmaceuticals Holding Corp.
1

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the first quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA. Finally, TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the second half of 2022. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox called TNX-801, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-1850, which are live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform.

1All of Tonix’s
product candidates are investigational new drugs or biologics and have not been
approved for any indication.

2Noyce RS, et
al. (2018) PLoS One. 13(1):e0188453

3Tulman ER, et
al. (2006) J Virol. 80(18):9244-58.PMID:16940536

4Noyce, RS, et
al. Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects
Macaques from Monkeypox* Presented as a poster at the American Society of
Microbiology BioThreats Conference – January 29, 2020, Arlington, VA.
(https://content.equisolve.net/tonixpharma/media/10929ac27f4fb5f5204f5cf41d59a121.pdf)

5Tonix Press
Release March 16, 202a
https://ir.tonixpharma.com/news-events/press-releases/detail/1255/tonix-pharmaceuticals-reports-positive-covid-19-vaccine

6Schrick L et
al. N Engl J Med. (2017) 377:1491.

7Qin et al. J. Virol. 89:1809
(2015).

8Jenner E. “An
Inquiry Into the Causes and Effects of the Variolae
 Vaccinae:
A Disease Discovered in Some of the Western Counties of England, Particularly
Gloucestershire, and Known by the Name of the Cow Pox.” London: Sampson Low,
1798.

9Brinkmann A et
al, Genome Biology (2020) 21:286 https://doi.org/10.1186/s13059-020-02202-0

10Duggan A et
al. Genome Biology (2020) 21:175 https://doi.org/10.1186/s13059-020-02079-z

11Tonix press
release. Dec 4, 2020
https://ir.tonixpharma.com/news-events/press-releases/detail/1236/vaccine-genome-researchers-report-99-7-colinear-identity

12Trindale GS et
al. Viruses (2016) (12). Pii: E328. PMID:27973399

13Esparza E, et
al Vaccine. (2017) 35(52):7222-7230.

14Esparza J et
al. Vaccine. (2020); 38(30):4773-4779.

15www.cdc.gov/poxvirus/monkeypox/about.html
16www.cdc.gov/smallpox/research/
17Mandavilli, A.
The New York Times. May 26, 2020. “Who is protected against monkeypox”

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward
Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris
(corporate)

Tonix Pharmaceuticals
investor.relations@tonixpharma.com

(862) 799-8599

Olipriya Das,
Ph.D. (media)

Russo Partners
Olipriya.Das@russopartnersllc.com

(646) 942-5588

Peter Vozzo
(investors)

ICR Westwicke
peter.vozzo@westwicke.com

(443) 213-0505

 

Source: Tonix Pharmaceuticals Holding Corp.


Release – Stream Hatchet Launches Stream Hatchet Brands – to Track Earned Media Value from Brand Advertisements In Streaming



Stream Hatchet Launches Stream Hatchet Brands – to Track Earned Media Value from Brand Advertisements In Streaming

Research, News, and Market Data on Engine Gaming & Media

Stream Hatchet Brands enables
the targeted performance measurement of over 2,300 major brands via logo
recognition models and chat analysis on video game streaming platforms

Barcelona, SPAIN – 8 June 2022 – Stream Hatchet, a wholly-owned subsidiary of Engine Gaming and Media, Inc. (“Engine” or the “Company”) (NASDAQ:GAME)(TSXV:GAME), today announced that it has launched Stream Hatchet Brands, a tool and comprehensive database that allows marketers to track earned media value from over 2,300 major brands on video game streaming platforms

Stream Hatchet Brands provides detailed information and curated data sets on the prominence of brand appearances within the top video game streamers, as well as the earned media value generated in each individual frame. This allows marketers to track brand logo impressions related to viewership and brand affinity and present them in dashboards

These dashboards can be filtered into specific categories and industry segments to enhance comparative analysis, and the final data can be processed into a variety of visuals and reports.

Stream Hatchet Brands features three advanced data curation methods:

  • Logo detection with frame by frame
    methodology
     – A bespoke model allows the tracking of brand logos by observing the stream frame by frame. Using this data, internal algorithms generate an earned media value providing a micro-level and highly accurate performance measurement.
  • Logo detection by logo presence
    methodology
     – In addition to tracking brand logos in streaming videos, Stream Hatchet Brands also tracks brand presence on a larger level, allowing brands to benchmark their presence against a broader quantity of live streaming platforms.
  • Chat analysis – Brand mentions are detected by analyzing the complete chat history of all channels, and Stream Hatchet Brands’ advanced methodology tracks specific brand mentions by analyzing the context of the chat to avoid tracking keywords that share the brand name.

More than ever, brands are leveraging gaming influencers and esports events to reach the core gaming audience, which is full of lucrative consumers for various brands,” said Eduard Monsterrat, CEO at Stream Hatchet. “Tracking earned media value on live streams has never been easy, but now with the launch of Stream Hatchet Brands, brand marketers have a simple way of accurately determining the level of brand lift they are generating through sponsorship activations. They can see where their logos appear on stream and how prominent they are compared to competitors, while also tracking brand affinity through audience mentions in chat.

“What makes our products unique”, Montserrat continued, “is our taxonomy and classification methodology. Our data experts spend a copious amount of time properly labelling each individual data point that flows through our reporting offerings, and we never sacrifice quality”.

About Stream Hatchet

Stream Hatchet is the market leader in live-streaming viewership data analytics for the world’s leading video game streaming platforms. Stream Hatchet provides deep insights to leading brands, creator networks, esports leagues, game publishers and other businesses measuring the impact of video game live streaming. Stream Hatchet is a wholly-owned subsidiary of Engine Gaming and Media. For more information, please visit www.streamhatchet.com.

About Engine Gaming and Media,
Inc.

Engine Gaming and Media, Inc. is traded publicly under the ticker symbol (NASDAQ: GAME) (TSX-V: GAME). Engine provides premium social sports and esports gaming experiences, as well as unparalleled data analytics, marketing, advertising, and intellectual property to support its owned and operated direct-to-consumer properties while also providing these services to enable its clients and partners. The company’s subsidiaries include Stream Hatchet, Sideqik, WinView, UMG Gaming, and Frankly Media. For more information, please visit www.enginegaming.com/

Press Kit: 
Media Kit

For further press information, please contact
Amy Ballantyne
Big Games Machine
Email: 
amy@biggamesmachine.com


Release – Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for Virology



Tonix Pharmaceuticals Announces Presentation of Licensed Antiviral Drug Technology at the 4th Symposium of the Canadian Society for Virology

Research, News, and Market Data on Tonix Pharmaceuticals

Oral Presentation Describes Activity of Wnt/?-Catenin Signaling Pathway Inhibitors Against SARS-CoV-2 in Cell
Culture and in an Animal Model

CHATHAM, N.J., June 08, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Tom Hobman, Ph.D., Professor, Department of Cell Biology, University of Alberta, presented data from his laboratory at The University of Alberta as a keynote presentation at the 4th Symposium of the Canadian Society for Virology held in Edmonton, Alberta, Canada on June 5, 2022. The oral presentation titled, “The
virus-host Interface: A treasure trove of novel antiviral targets,”
 includes research sponsored by Tonix Pharmaceuticals focused on the development and testing of Wnt/?-Catenin signaling pathway inhibitors as broad-spectrum antivirals against SARS-CoV-2 and other emerging viruses. Tonix has previously announced that it exercised an option to license the antiviral technology platform A copy of the presentation is available on the Tonix Pharmaceuticals corporate website at www.tonixpharma.com.

“We are excited by the progress of Professor Hobman and his colleagues at The University of Alberta on the further testing of Wnt/?-Catenin signaling pathway inhibitors as broad-spectrum antivirals,” said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. “Professor Hobman presented data showing that three different Wnt/?-Catenin inhibitor drug candidates decreased lung infection in an animal model of SARS-CoV-2 infection. The set of Wnt/?-Catenin inhibitors tested by Professor Hobman include drugs that have been previously studied in humans for other indications including one drug that is FDA approved. Professor Hobman believes that reducing ?-Catenin levels with Wnt-inhibitor drugs induces peroxisome proliferation and enhances the interferon response. Previously, SARS-CoV-2 was shown to be sensitive to inhibition by interferon2. Professor Hobman reported that Wnt/?-Catenin inhibitor and peroxisome inducing drugs also inhibit Zika virus (ZIKV) and Mayaro (MAYV) virus in cell culture. Tonix is excited to have sponsored Professor Hobman’s research involving Wnt/?-Catenin signaling pathway inhibitors as broad-spectrum antivirals and to have licensed the technology. We look forward to working with Professor Hobman to try to bring one or more of these candidate drugs to clinical testing.”

About Tonix
Pharmaceuticals Holding Corp.
1

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the first quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA. Finally, TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the second half of 2022. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox called TNX-801, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-1850, which are live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform.

1All of Tonix’s
product candidates are investigational new drugs or biologics and have not been approved
for any indication.

2Lokugamage, K. G. et al., (2020). Journal of
virology, 94 (23), [e01410]. https://doi.org/10.1128/JVI.01410-20

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward
Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Contacts

Jessica Morris
(corporate)

Tonix Pharmaceuticals
investor.relations@tonixpharma.com

(862) 799-8599

Olipriya Das,
Ph.D. (media)

Russo Partners
Olipriya.Das@russopartnersllc.com

(646) 942-5588

Peter Vozzo
(investors)

ICR Westwicke
peter.vozzo@westwicke.com

(443) 213-0505

 

Source: Tonix Pharmaceuticals Holding Corp.


PDS Biotechnology Corp (PDSB) – Conference Call Clarifies Data and Mechanism of PDS0101

Wednesday, June 08, 2022

PDS Biotechnology Corp (PDSB)
Conference Call Clarifies Data and Mechanism of PDS0101

PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer and infectious disease immunotherapies based on the Company’s proprietary Versamune® and Infectimune™ T-cell activating technology platforms. Our Versamune®-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune® and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The Company’s pipeline products address various cancers including HPV16-associated cancers (anal, cervical, head and neck, penile, vaginal, vulvar) and breast, colon, lung, prostate and ovarian cancers.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

PDS Held A Conference Call Following ASCO Data Presentations.  On June 7, PDS management held a conference call to discuss the full data from its presentations at the American Society for Clinical Oncology (ASCO) meeting on June 5 and 6.  The presentations were from the Phase 2 VERSATILE-002 trial testing PDS0101 in head and neck cancer and the Phase 2 Triple Combination trial testing PDS0101 with two immune modulating drugs in multiple tumor types.

Two Trials Presented Data At ASCO.  PDS0101 was developed using the PDS Versamune technology to stimulate an immune response to HPV16, an immune marker found on human papilloma virus (HPV) related cancers.  The VERSATILE-002 trial tested PDS0101 the combination with Merck’s pembrolizumab (Keytruda), using the checkpoint inhibitor to make the tumor recognizable to the immune system along with PDS0101 to improve the immune response and kill the tumor cells….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Artificial Intelligence Language Translation Involves Machines First Hallucinating


Image Credit: Lauren Hinkel (MIT)


Machine Hallucinating to Better Translate Languages

Lauren Hinkel | MIT-IBM Watson AI Lab

As babies, we babble and imitate our way of learning languages. We don’t start off reading raw text, which requires fundamental knowledge and understanding about the world, as well as the advanced ability to interpret and infer descriptions and relationships. Rather, humans begin our language journey slowly, by pointing and interacting with our environment, basing our words and perceiving their meaning through the context of the physical and social world. Eventually, we can craft full sentences to communicate complex ideas.

Similarly, when humans begin learning and translating into another language, the incorporation of other sensory information, like multimedia, paired with the new and unfamiliar words, like flashcards with images, improves language acquisition and retention. Then, with enough practice, humans can accurately translate new, unseen sentences in context without the accompanying media; however, imagining a picture based on the original text helps.

This is the basis of a new machine learning model, called VALHALLA, by researchers from MIT, IBM, and the University of California at San Diego, in which a trained neural network sees a source sentence in one language, hallucinates an image of what it looks like, and then uses both to translate into a target language. The team found that their method demonstrates improved accuracy of machine translation over text-only translation. Further, it provided an additional boost for cases with long sentences, under-resourced languages, and instances where part of the source sentence is inaccessible to the machine translator.

As a core task within the AI field of natural language processing (NLP), machine translation is an “eminently practical technology that’s being used by millions of people every day,” says study co-author Yoon Kim, assistant professor in MIT’s Department of Electrical Engineering and Computer Science with affiliations in the Computer Science and Artificial Intelligence Laboratory (CSAIL) and the MIT-IBM Watson AI Lab. With recent, significant advances in deep learning, “there’s been an interesting development in how one might use non-text information — for example, images, audio, or other grounding information — to tackle practical tasks involving language” says Kim, because “when humans are performing language processing tasks, we’re doing so within a grounded, situated world.” The pairing of hallucinated images and text during inference, the team postulated, imitates that process, providing context for improved performance over current state-of-the-art techniques, which utilize text-only data.

This research will be presented at the IEEE / CVF Computer Vision and Pattern Recognition Conference this month. Kim’s co-authors are UC San Diego graduate student Yi Li and Professor Nuno Vasconcelos, along with research staff members Rameswar Panda, Chun-fu “Richard” Chen, Rogerio Feris, and IBM Director David Cox of IBM Research and the MIT-IBM Watson AI Lab.

 

Learning to Hallucinate
from Images

When we learn new languages and to translate, we’re often provided with examples and practice before venturing out on our own. The same is true for machine-translation systems; however, if images are used during training, these AI methods also require visual aids for testing, limiting their applicability, says Panda.

“In real-world scenarios, you might not have an image with respect to the source sentence. So, our motivation was basically: Instead of using an external image during inference as input, can we use visual hallucination — the ability to imagine visual scenes — to improve machine translation systems?” says Panda.

To do this, the team used an encoder-decoder architecture with two transformers, a type of neural network model that’s suited for sequence-dependent data, like language, that can pay attention key words and semantics of a sentence. One transformer generates a visual hallucination, and the other performs multimodal translation using outputs from the first transformer.

During training, there are two streams of translation: a source sentence and a ground-truth image that is paired with it, and the same source sentence that is visually hallucinated to make a text-image pair. First the ground-truth image and sentence are tokenized into representations that can be handled by transformers; for the case of the sentence, each word is a token. The source sentence is tokenized again, but this time passed through the visual hallucination transformer, outputting a hallucination, a discrete image representation of the sentence. The researchers incorporated an autoregression that compares the ground-truth and hallucinated representations for congruency — e.g., homonyms: a reference to an animal “bat” isn’t hallucinated as a baseball bat. The hallucination transformer then uses the difference between them to optimize its predictions and visual output, making sure the context is consistent.

The two sets of tokens are then simultaneously passed through the multimodal translation transformer, each containing the sentence representation and either the hallucinated or ground-truth image. The tokenized text translation outputs are compared with the goal of being similar to each other and to the target sentence in another language. Any differences are then relayed back to the translation transformer for further optimization.

For testing, the ground-truth image stream drops off, since images likely wouldn’t be available in everyday scenarios.

“To the best of our knowledge, we haven’t seen any work which actually uses a hallucination transformer jointly with a multimodal translation system to improve machine translation performance,” says Panda.

 

Visualizing the
Target Text

To test their method, the team put VALHALLA up against other state-of-the-art multimodal and text-only translation methods. They used public benchmark datasets containing ground-truth images with source sentences, and a dataset for translating text-only news articles. The researchers measured its performance over 13 tasks, ranging from translation on well-resourced languages (like English, German, and French), under-resourced languages (like English to Romanian) and non-English (like Spanish to French). The group also tested varying transformer model sizes, how accuracy changes with the sentence length, and translation under limited textual context, where portions of the text were hidden from the machine translators.

The team observed significant improvements over text-only translation methods, improving data efficiency, and that smaller models performed better than the larger base model. As sentences became longer, VALHALLA’s performance over other methods grew, which the researchers attributed to the addition of more ambiguous words. In cases where part of the sentence was masked, VALHALLA could recover and translate the original text, which the team found surprising.

Further unexpected findings arose: “Where there weren’t as many training [image and] text pairs, [like for under-resourced languages], improvements were more significant, which indicates that grounding in images helps in low-data regimes,” says Kim. “Another thing that was quite surprising to me was this improved performance, even on types of text that aren’t necessarily easily connectable to images. For example, maybe it’s not so surprising if this helps in translating visually salient sentences, like the ‘there is a red car in front of the house.’ [However], even in text-only [news article] domains, the approach was able to improve upon text-only systems.”

While VALHALLA performs well, the researchers note that it does have limitations, requiring pairs of sentences to be annotated with an image, which could make it more expensive to obtain. It also performs better in its ground domain and not the text-only news articles. Moreover, Kim and Panda note, a technique like VALHALLA is still a black box, with the assumption that hallucinated images are providing helpful information, and the team plans to investigate what and how the model is learning in order to validate their methods.

In the future, the team plans to explore other means of improving translation. “Here, we only focus on images, but there are other types of a multimodal information — for example, speech, video or touch, or other sensory modalities,” says Panda. “We believe such multimodal grounding can lead to even more efficient machine translation models, potentially benefiting translation across many low-resource languages spoken in the world.”


Suggested Content



The Most Effective Artificial Intelligence Will Never Exist in the Cloud



How AI is Shaping the Cybersecurity Arms Race





Stock Market Signals Gun Law Tightening Unlikely



Industries that Benefit from Digital Twin Applications

 

Stay up to date. Follow us:

 

Michael Burry Uses Burgernomic’s logic to Evaluate the US Dollar


Image Credit: Marc Buehler (Flickr)


Michael Burry Tweets About the Weak Dollar While Mainstream News Discusses Dollar Strength

The US Dollar ($USD) has been strengthening against most major currencies of late. But, it can be argued, the currency strength directly against other currencies may not be a useful test for investors or consumers. Michael Burry, the fund manager of “The Big Short” fame, took to Twitter Tuesday to transform this talk of a stronger dollar. His tweet argues that those thinking the $USD is strong are using the wrong yardstick. US currency, he suggests, is only strong on a relative basis to other weakening currencies, and rampant inflation is actually eroding its purchasing power and its value.

Cheeseburger in Pandemonium

Burry’s words are reminiscent of The Big Mac Index. This is a measure lightheartedly created in 1986 by The Economist magazine to show currency misalignment between nations using a Macdonald’s menu item as the control. Over 36 years, it has devolved into a more simplified version called Burgernomics. Burgernomics shows the change in a currency’s direct purchasing power and, therefore, value change based on the cost of a cheeseburger.

Burry tweeted on June 7th, “When you see mention of
the strong dollar, the almighty dollar, please remember this is only in
relation to other fiat currencies,” he said. “The dollar is not at all
strong, and it is not getting stronger. We all see it every single day in
prices of everything.”
Burry has been very vocal since early 2020 about his concerns about the economic impact of steps taken at all levels in Washington.

Through May and continuing into June, the US dollar, measured against other currencies, hit 20-year highs. Its accelerated strength against other currencies is said to demonstrate its appeal as a haven in a volatile world. It also has gained natural strength from rising interest rates available in dollar-denominated assets.


Source: Koyfin

Burry’s point is that a dollar may be worth more in euros or yen than before, but it buys far less due to the soaring prices of food, gas, housing, and many other goods and services. The expression “picking the cleanest dirty shirt” was used by many economists after 2008 to explain why foreign assets were invested in the US despite US troubles. The expression doesn’t suggest the US economy was at all good, it instead emphasizes that it was just best.


Source: Twitter

This thinking is not out of line with another widely followed investor, Warren Buffett. At the Berkshire Hathaway annual meeting, the Oracle of Omaha was quoted as saying. “Inflation swindles the bond investor … it swindles the person who keeps their cash under their mattress, it swindles almost everybody.”

Further Warnings from Burry

Burry, who is known to go on a tweeting frenzy only to delete them by day’s end, has left the above tweet available on his account. He recently highlighted that Americans are saving less, borrowing more, and could virtually exhaust their savings before the end of this year. He explained, that trend threatens to slash consumer spending and pile more pressure on corporate earnings.

Take Away

The well-followed hedge fund manager and founder of Scion Asset Management, LLC took to Twitter to give a different view than most often shown in financial news. Burry had frequently called out the economic cheerleaders and irrational speculation in the markets during the pandemic. He once discussed at length with Bloomberg how the reaction to coronavirus would eventually be worse
than the disease
. He has compared
index funds
to the real estate crisis. And he also bemoaned the “greatest speculative bubble of all time in all things” last summer, and warned owners of meme stocks and cryptocurrencies that they were headed towards the “mother of all crashes.”

He is never on CNBC or FOX Business News, but his thoughts and tweets are worth paying attention to. Channelchek will selectively highlight those thoughts when they seem relevant to our subscribers.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Michael Burry’s Stock Market Holdings (Filed May 16, 2022)



Michael Burry vs Cathie Wood is Not an Even Competition




Is the Index Bubble Michael Burry Warned About Still Looming?



SEC Pokes Fun at Investors, Draws Controversy


Sources

https://www.economist.com/big-mac-index

https://www.reuters.com/business/buffett-says-inflation-an-issue-berkshire-it-swindles-almost-everybody-2022-04-30/

Stay up to date. Follow us: